VTRS

NASDAQ · Pharmaceuticals

Viatris Inc

S&P 500 Large-Cap Stocks Blue Chip Stocks Pharmaceutical Stocks Healthcare Stocks Best Dividend Stocks Highest Dividend Yield

$17.17

-0.22 (-1.27%)

As of May 9, 1:07 AM ET ·

Financial Highlights (FY 2026)

Revenue

14.02B

Net Income

-3,445,393,540

Gross Margin

39.5%

Profit Margin

-24.6%

Rev Growth

-4.2%

D/E Ratio

0.98

Revenue & Net Income

Margin Trends

	FY 2026	FY 2025	FY 2024	FY 2023
Gross Margin	39.5%	39.5%	35.8%	35.8%
Operating Margin	-19.3%	-17.4%	29.8%	37.8%
Profit Margin	-24.6%	-23.4%	27.9%	27.3%

Income Statement

	FY 2026	FY 2025	FY 2024	FY 2023
Revenue	14.02B	14.63B	3.47B	3.37B
Gross Profit	5.54B	5.79B	1.24B	1.20B
Operating Income	-2,710,897,605	-2,546,772,280	1.03B	1.27B
Net Income	-3,445,393,540	-3,236,799,776	966.90M	917.66M
Gross Margin	39.5%	39.5%	35.8%	35.8%
Operating Margin	-19.3%	-17.4%	29.8%	37.8%
Profit Margin	-24.6%	-23.4%	27.9%	27.3%
Rev Growth	-4.2%	-4.2%	-2.8%	+22.9%

Balance Sheet

	FY 2026	FY 2025	FY 2024	FY 2023
Total Debt	4.88B	4.88B	4.37B	3.63B
Total Equity	4.98B	4.98B	12.59B	11.78B
D/E Ratio	0.98	0.98	0.35	0.31

Cash Flow

	FY 2026	FY 2025	FY 2024	FY 2023
EBITDA	-387,526,445	-384,290,316	1.51B	1.62B
Free Cash Flow	—	—	925.81M	1.00B